In conclusion, we demonstrated that PD1 + TIM3+/T, TIGIT + T/T, and IL-6 levels after immunotherapy can serve as predictors of efficacy in patients with hepatocellular carcinoma. This evidence concerns the gene HAVCR2 and hepatocellular carcinoma.